Medicine composition and preparation and use thereof

A composition and medicine technology, applied in the field of pharmaceutical compositions containing mannan peptides and their preparation, can solve the problems of large oral dose, complex components and the like, and achieve the effects of exact curative effect, mild side effects and low cost

Inactive Publication Date: 2003-09-03
成都利尔药业有限公司
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Chinese patent 98121898 discloses "a kind of compound mannan peptide oral liquid", which contains multiple components, and its mannan peptides are from basidiomycete fungi, Septobasidiomycetes fungi, Polyporacea fungi, and Umbelliferae fungi. complex, large oral dose

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 2

[0042] The ethanol concentration in the extraction process of step ii is 60-99.9%. The appraisal of the semi-finished product and finished product that the above-mentioned method of example 2 obtains 1, the appraisal of semi-finished product:

[0043] i. Absorbance measurement: Take an appropriate amount of semi-finished product, add water to make a solution containing 0.4 mg per 1 ml, and according to the spectrophotometry (Chinese Pharmacopoeia 2000 Edition, Part II, Appendix VI A), at the wavelength of 260 nm, its absorbance should not be greater than 0.25, at a wavelength of 280nm, its absorbance should not be greater than 0.20.

[0044] ii. Content determination:

[0045]a. Preparation of the reference solution In a measuring bottle, add water to the mark and shake. Each 1ml contains 50μg of mannose.

[0046] b. Preparation of the test product Take an appropriate amount of this product, accurately weigh it, and dissolve it in water to make a solution containing 40μg p...

experiment example 2

[0123] Oral administration of the medicine of the present invention has obvious inhibitory effect on the growth of Ehrlich ascites carcinoma solid tumor in mice; it can enhance the phagocytic function of the reticuloendothelial system and the phagocytic function of macrophages in normal and tumor-bearing mice, and increase the production of antibody-hemolysin in mice. It can significantly improve the immune activity such as the ability of spleen cells to produce IL-2 in normal and tumor-bearing mice; it can also promote the proliferation of hematopoietic stem cells in mice. Experimental example 2 Summary of clinical verification data of the drug of the present invention

[0124] Leukopenia and low immune function, especially after radiotherapy and chemotherapy, are more common in clinical practice. This type of patients has the characteristics of severe disease and difficult to recover, and the treatment is more difficult. Therefore, it is of great clinical significance to st...

experiment example 3

[0128] As a preparation for treating leukopenia and low immune function after radiotherapy and chemotherapy, the medicine of the invention has satisfactory curative effect, is convenient and safe to take, and provides a new treatment option for the treatment of clinical radiochemical leukopenia and low immune function. Experimental Example 3 Toxicological study of the medicine of the present invention

[0129] 1. Acute toxicity

[0130]After oral administration of 5 g / Kg of the drug of the present invention in mice and rats, there was no adverse reaction; after intramuscular injection of 2 g / Kg of the drug of the present invention in mice and rats, only a few mice died, indicating that oral or intramuscular injection of the drug caused toxicity. are all low.

[0131] Mice and rats were intravenously injected with the drug of the present invention, and the mortality rate was not proportional to the dose. Intravenous injection of 5.2mg / Kg of the medicine of the present inventi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A composite medicine in the form of capsules contains mannosan peptide, which is prepared from the fermented substance of streptococcus hemolyticus-alpha-hemolysis through extracting and refining. Its preparing process and application are also disclosed. Its advantages are sure curative effect and low dosage.

Description

technical field [0001] The present invention provides a pharmaceutical composition, a preparation method and application thereof, in particular, a pharmaceutical composition containing mannan peptide and its preparation method and application. Background technique [0002] With changes in the environment, the incidence of human tumors is increasing, and the age of onset is lower than in the past. Finding safe and effective anti-tumor drugs is the goal of mankind. [0003] The use of human defense mechanisms for tumor treatment was advocated by the National Cancer Institute in the late 1970s and gradually developed worldwide in the 1980s. Japan is at the forefront in the research and development of anti-tumor using immune activators, and has been approved for production and marketing. The streptococcus preparation of hemolytic streptococcus (OK-432) was launched in 1975, and the fungal polysaccharide preparation of Yunzhi intracellular polysaccharide...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/16A61P7/06A61P35/00A61P37/04C12P21/02
Inventor 陈云华李军刘艳
Owner 成都利尔药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap